in close to 20 publications including approximately 600 patients, most with dementia. Contrary to these 20 published reports on the brain biopsy taken during life, post mortem validations of these findings are sparse. Warren et al. 19 reported that out of their own 90 consecutive cerebral biopsies obtained from patients with dementia, only 10 subjects had undergone post-mortem neuropathological examination.
The agreement rate between biopsy and autopsy findings in these 10 cases was 40 %.
Normal Pressure Hydrocephalus -A Window for Brain Biopsy
Normal pressure hydrocephalus (NPH) is a damaging neurodegenerative disorder that can lead to dementia and typically presents with a clinical triad of symptoms including cognitive impairment, gate difficulty and urinary incontinence in various combinations. 21, 22 Brain imaging demonstrates dilated brain ventricles and obliterated cortical sulci. NPH may appear after brain insult such as subarachnoid haemorrhage, trauma or infection (secondary NPH [sNPH]) or without any known predisposing factors (idiopathic NPH [iNPH] ). 21 Contrary to other forms of dementia the symptoms can be alleviated by shunt surgery; however, the outcome of treatment varies considerably and is highly dependent on patient selection. [23] [24] [25] Differentiation between NPH and AD can be difficult, especially when cognitive symptoms are atypical for AD, motor symptoms dominate and there is central atrophy in brain imaging.
Furthermore, the differential diagnosis between NPH and vascular dementia (VaD) can be even more difficult. 26 Vascular changes in brain imaging are frequently seen concomitant pathology, similar to AD-related changes in brain biopsy.
Currently, brain biopsy taken during shunt surgery or diagnostic procedures for NPH has only limited value in the differential diagnosis of NPH and VaD but offer an opportunity to assess the AD-related pathology in patients with signs of cognitive impairment or potential pre-clinical stage of AD. AD-related lesions are seen in up to 70 % of NPH patients depending on patient selection and staining methods used.
Since 1991 the diagnostic work-up of iNPH at Kuopio University Hospital (KUH) Neurosurgery Department has included sampling of a small right frontal cortical biopsy and 24-hour intracranial pressure (ICP) monitoring. 18, 20, [27] [28] [29] Prior to placement of intra-ventricular catheter through a burr hole, cylindrical cortical brain biopsies were obtained with forceps (2-5 mm in diameter and 3-7 mm in length) and currently by standard disposable biopsy needle (biopsy dimensions 1-2 x 5-10 mm, see Figure 1 ). As of 2010 the KUH Neurosurgery NPH Registry (www.uef.fi/nph) kept records of over 600 consecutive patients evaluated for suspected NPH from a defined catchment population.
The patients are actively followed-up and the clinical data are carefully re-evaluated by a neurologist sub-specialised in memory disorders to detect the development of cognitive impairment sufficient for the diagnosis of any form of dementia according to DSM-IV criteria. 30 The specific forms of dementia are diagnosed according to established criteria. [31] [32] [33] [34] Brain Biopsy in the Diagnosis of Alzheimer's Disease and Aβ alone (OR 11) were independent risk factors for AD. In the prediction of AD, Aβ together with HPτ was specific (98 %) but rather insensitive (36 %), while Aβ alone had lower specificity (69 %) but higher sensitivity (87 %). The predictive value was notably higher in patients who were ≤65 years of age. In the absence of Aβ and HPτ only one of the 77 patients developed AD.
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Of the 433 biopsied patients, 219 subjects with apparent NPH according to ICP measurement received a shunt, and 26 of them also finally developed AD. This indicates that NPH and AD are basically different entities, but there is some overlap. 20 In addition, when the diagnostic setup of the patient otherwise indicates NPH, the pathological findings of the biopsy should not be used as an exclusion criteria for shunt but taken into consideration during follow-up, especially if cognitive status deteriorates in spite of a shunt. After all, with the most severe AD-related pathology, NPH or at least a positive response to a shunt, is unlikely. 20, 35 We made the final clinical diagnosis according to all available medical data before and after the biopsy including the final cognitive status. It
Amyloid-β and Hyperphosphorylated Tau in the Prediction of Alzheimer's Disease A study using silver stain methods that are less sensitive than Biopsy can be performed using small forceps preferably with a small surgical (dura) knife avoiding the crushing of the tissue. The easiest way to obtain a standard biopsy is a cutting biopsy needle (at least 14
Gauge [G]) giving 1-2 x 5-10 mm cylindrical transcortical samples with underlying white matter (see Figure 1) . When the primary indication of the surgical procedure is biopsy, e.g. in progressive dementia with an undefined origin, a larger sample is usually needed, by less invasive diagnostic methods .
Processing of the Sample
Ideally the fresh sample is transferred directly to the pathology laboratory with as short delay as possible (less than 60 minutes).
Thus, the sample can be processed by a pathologist, divided into paraffin block and fresh frozen sample (cortex and white matter in different tubes). A formalin fixed (FF) sample alone is sufficient if only haematoxylin-eosin (HE), silver and IHC methods are going to be used.
For special research purposes immediately (e.g. in an operating theatre) frozen samples might be considered.
Neurodegenerative Disease Alzheimer's Disease Immunohistochemical Staining Extracellular accumulation of Aβ could be divided into fleecy, diffuse and dense plaques (see Figure 2 ). For Aβ, several antibodies binding to different epitopes are available (e.g. 6F3D, M0872, Dako; dilution 1:100; pre-treatment 80 % formic acid for one hour). Non-specific labelling, especially if seen intracellularly, should be excluded using several antibodies if needed. 39 Fibrillar Aβ can be detected by congo red or thioflavin-S. Silver staining can be used for comparison of historical studies.
Intraneuronal hyperphosphorylated tau (HPτ, see Figure 3 ) can be stained by AT8 (3Br-3, Innogenetics; dilution 1:30). For differential diagnosis, p62 (3/p62 lck ligand, BD Bioscience) seems to be a sensitive marker of neurodegeneration (see Figure 4) . In cases where brain biopsy is the primary indication for surgery in the diagnosis of dementia, see updated review by Schott et al. 2010 40 for an optimised protocol.
Histological Evaluation
The 
Procedure-related Risks
In our own series of 468 patients, 20 the management mortality rate up to 12 months associated with the biopsy and 24-hour ICP monitoring was 0.6 % (three of 468). Two patients developed intracerebral haematoma and died at two and eight months, respectively. One case of fatal ischaemic stroke developed during ICP monitoring. One patient developed post-operative bacterial meningitis (0.2 %) but did not deteriorate clinically. Importantly, these complications were not directly related with biopsy itself and could have happened without it.
However, complication rates of over 10 % are reported, particularly when rather large samples including leptomeninges, cortex and white matter had been resected. 19 In addition to haemorrhage and infection, seizures have also been reported.
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Future Perspectives
Clinical dementia of AD is usually preceded by deterioration of episodic memory, and a correct diagnosis at the mild cognitive impairment (prodromal AD) phase or even pre-clinically would lengthen the window for potential mechanism-based interventions to inhibit AD pathogenesis. 9 The new biologically targeted therapies emphasise the early and specific diagnosis. 46 Brain biopsy is a potential option in the investigation of dementia when a specific diagnosis cannot be made by standard non-invasive means, 19 and it can be used to validate less invasive markers. 18 When available, brain biopsy may allow earlier diagnosis in specific cases and help in the stratification of the patients according to the inclusion and exclusion criteria of future clinical trials, i.e. known Aβ status when planning a treatment strategy affecting Aβ production and/or metabolism. 20 The sensitivity and specificity of Aβ and tau presented 20 are under the threshold requested to be considered biomarkers, and lower than sensitivity and specificity of the same proteins in cerebrospinal fluid. In that study the patient population was not originally typical subjects with suspected AD, instead it was a heterogeneous sample of various neurodegenerative disorders.
Imaging-targeted brain biopsies of a few millimetres can be obtained Amyloid-β and Hyperphosphorylated Tau in the Prediction of Alzheimer's Disease
